Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 533Squamous Cell Carcinoma of Head and Neck 274Head and Neck Neoplasms 253Lung Neoplasms 238Uterine Cervical Neoplasms 178Stomach Neoplasms 168Esophageal Neoplasms 160Nasopharyngeal Carcinoma 123Urinary Bladder Neoplasms 116Esophageal Squamous Cell Carcinoma 115Neoplasms 113Small Cell Lung Carcinoma 104Breast Neoplasms 92Neoplasm Metastasis 90Ovarian Neoplasms 89Cholangiocarcinoma 76Carcinoma, Squamous Cell 76Pancreatic Neoplasms 72Biliary Tract Neoplasms 70Mesothelioma, Malignant 57Oropharyngeal Neoplasms 56Carcinoma 55Adenocarcinoma Of Esophagus 52Recurrence 47Parkinson Disease 4, Autosomal Dominant Lewy Body 47Carcinoma, Ovarian Epithelial 45Nasopharyngeal Neoplasms 41Lymphoma 41Adenocarcinoma of Lung 41Triple Negative Breast Neoplasms 38

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bladder Adenocarcinoma × Cisplatin × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡